Local control strategies for management of NSCLC with oligoprogressive disease

At diagnosis, up to 50% of patients with non-small cell lung cancer (NSCLC) present with advanced stage [1]. Metastatic NSCLC is an heterogeneous disease and its prognosis depends on predictive biomarkers such as PD-L1 status and the presence of genomic alterations, as well as prognostic markers based on the tumor burden defined by the number of metastatic lesions [2 –4]. In the recent decade, the introduction of immune checkpoint blockers (ICB) and targeted therapies for oncogene-addicted NSCLC have shifted the treatment paradigm and prognosis of patients with advanced NSCLC.

Source: Cancer Treatment Reviews - September 1, 2023 Category: Cancer & Oncology Authors: Antoine Mavrikios, Jordi Remon, Cl ément Quevrin, Olaf Mercier, Lambros Tselikas, Angela Botticella, Eliot Nicolas, Eric Deutsch, Benjamin Besse, David Planchard, Fabrice Barlesi, Cécile Le Péchoux, Antonin Levy Tags: Anti-tumour Treatment Source Type: research